Christopher E. Diamantis - 17 Sep 2021 Form 4 Insider Report for Rennova Health, Inc.

Role
Former 10% Owner
Signature
/s/ Christopher E. Diamantis
Issuer symbol
N/A
Transactions as of
17 Sep 2021
Net transactions value
$0
Form type
4
Filing time
30 Sep 2021, 16:15:31 UTC
Previous filing
27 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding RNVA Common Stock 95,450,000 17 Sep 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RNVA Warrants to Purchase Common Stock 47,500,000 17 Sep 2021 Common Stock 47,500,000 $0.007000 Direct F2
holding RNVA Series M Convertible Redeemable Preferred Stock 20,180 17 Sep 2021 Common Stock Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Christopher E. Diamantis is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This Form 4 is being filed to reflect the fact that, as of September 17, 2021, Mr. Diamantis beneficially owned less than 10% of the Common Stock of the Issuer. Mr. Diamantis has not effected any transactions in the securities of the Issuer since the August 27, 2021 Exchange Agreement reported on his prior Form 4. Due to conversions of the Issuer's preferred stock by parties other than Mr. Diamantis, the Issuer's outstanding Common Stock has increased dramatically. As of September 17, 2021, there were 1,057,349,999 shares of Common Stock issued and outstanding and, as a result, Mr. Diamantis' beneficial ownership has decreased to below 10%.
F2 The exercise of the Warrants and the conversion of the Series M Convertible Redeemable Preferred Stock (the "Series M Preferred Stock") are each subject to ownership blockers of 4.99%. As a result, they are not exercisable or convertible as of September 17, 2021. The Series M Preferred Stock has no stated maturity date.
F3 The conversion price of the Series M Preferred Stock fluctuates with the price of the Common Stock.